Mecanismos moleculares asociados al síndrome metabólico
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (1)
2017
-
Inhibition of T-Cell activation by the CTLA4-Fc abatacept is sufficient to ameliorate proteinuric kidney disease
American Journal of Physiology - Renal Physiology, Vol. 312, Núm. 4, pp. F748-F759